DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Guanfacine (Guanfacine Hydrochloride) - Summary

 
 



GUANFACINE SUMMARY

Guanfacine hydrochloride is a centrally acting antihypertensive with α -adrenoceptor agonist properties in tablet form for oral administration.

Guanfacine hydrochloride tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.


See all Guanfacine indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Guanfacine

Renovascular Hypertension Caused by Compressive Adenopathy
Source: Medscape Critical Care Headlines [2016.08.19]
Was this 28-year-old patient's abdominal mass related to his encephalopathic symptoms and new-onset hypertension?
Applied Radiology

Study suggests ways to block hypertension in those with sleep apnea
Source: Hypertension News From Medical News Today [2016.08.17]
Obstructive sleep apnea - a disorder that affects nearly one out of four people between the ages of 30 and 70 - is a common cause of high blood pressure. In the Aug.

Hypertension prevalence higher in lower-income countries for the first time
Source: Hypertension News From Medical News Today [2016.08.09]
New research indicates that the prevalence of high blood pressure in low- and middle-income countries has overtaken that of high-income countries.

To beat hypertension, take the 'clinic' to the people
Source: Hypertension News From Medical News Today [2016.08.08]
Study aims to eliminate racial differences in outcomes of blood pressure control programs.

Can drugs that treat hypertension also treat depression?
Source: Depression News From Medical News Today [2016.08.01]
In the current issue of Psychotherapy and Psychosomatics, the relationship of drugs that are generally used for treating hypertension (angiotensin converting enzyme inhibitors) are examined in...

more news >>

Published Studies Related to Guanfacine

Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form. [2014]
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: These results provide further support for the demonstrated efficacy

Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. [2013]
CONCLUSIONS: GXR administered either in the morning or evening was associated

Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. [2013]
induced craving and have reduced opiate relapse in small clinical trials... CONCLUSIONS: Adding guanfacine to naltrexone did not improve treatment retention

Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.

more studies >>

Clinical Trials Related to Guanfacine

PK/PD Comparison of Guanfacine ER and IR [Active, not recruiting]
Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). [Completed]
This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride. The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U. S. Food and Drug Administration (FDA) for use in adults.

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence [Completed]
The purpose of this study is to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving as compared to baseline.

Does Guanfacine Attenuate Stress-Induced Drinking? [Recruiting]
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour self-administration period across stress and neutral/relaxing conditions.

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) [Recruiting]
Combination of guanfacine with opioid medication as a standard treatment for chronic pain.

more trials >>

Reports of Suspected Guanfacine Side Effects

Confusional State (3)Dyspepsia (3)Coordination Abnormal (3)Swelling Face (3)Swollen Tongue (3)Blood Pressure Decreased (3)Complex Partial Seizures (3)Sedation (2)Formication (2)LIP Swelling (1)more >>


Page last updated: 2016-08-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015